,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': 'Proposal arose from a subcommittee recommendation.', 'fs': 'Proposal arose from a subcommittee recommendation.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2015', 'fs': 'May 2015', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbLUAQ'}, 'Id': 'a0P2P000005htbLUAQ', 'Event_Date__c': '2015-05-11', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'Proposal arose from a subcommittee recommendation.', 'Formatted_Date__c': 'May 2015', 'Status_History__c': 'a132P000000AqvoQAC'}, 'change': None}]",May 2015,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Subcommittee recommended the Special Authority for valganciclovir be amended to include renewal criteria for patients who had undergone a lung transplant and received pulse methylprednisolone for acute rejection after the initial 6 months of CMV prophylaxis and requires a further 90 days of  valganciclovir for CMV prophylaxis.    Also recommended asking the Anti-Infective Subcommittee for advice on widening valganciclovir to other organ transplant recipients.', 'fs': 'The Subcommittee recommended the Special Authority for valganciclovir be amended to include renewal criteria for patients who had undergone a lung transplant and received pulse methylprednisolone for acute rejection after the initial 6 months of CMV prophylaxis and requires a further 90 days of  valganciclovir for CMV prophylaxis.    Also recommended asking the Anti-Infective Subcommittee for advice on widening valganciclovir to other organ transplant recipients.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-transplant-immunosuppressant-subcommittee-minutes-2015-6.pdf"" target=""_blank"">Transplant Immunosuppressant Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-transplant-immunosuppressant-subcommittee-minutes-2015-6.pdf"" target=""_blank"">Transplant Immunosuppressant Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2015', 'fs': 'May 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Transplant Immunosuppressant Subcommittee at meeting Monday 11 May 2015.', 'fs': 'Clinical advice received from Transplant Immunosuppressant Subcommittee at meeting Monday 11 May 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbMUAQ'}, 'Id': 'a0P2P000005htbMUAQ', 'Event_Date__c': '2015-05-11', 'Event_Description__c': 'Clinical advice received from Transplant Immunosuppressant Subcommittee at meeting Monday 11 May 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-transplant-immunosuppressant-subcommittee-minutes-2015-6.pdf"" target=""_blank"">Transplant Immunosuppressant Subcommittee minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Summary__c': 'The Subcommittee recommended the Special Authority for valganciclovir be amended to include renewal criteria for patients who had undergone a lung transplant and received pulse methylprednisolone for acute rejection after the initial 6 months of CMV prophylaxis and requires a further 90 days of  valganciclovir for CMV prophylaxis.    Also recommended asking the Anti-Infective Subcommittee for advice on widening valganciclovir to other organ transplant recipients.', 'Formatted_Date__c': 'May 2015', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000AqvpQAC'}, 'change': None}, {'Summary': {'s': 'Accepted Subcommittee recommendation.', 'fs': 'Accepted Subcommittee recommendation.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2015', 'fs': 'Aug 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbOUAQ'}, 'Id': 'a0P2P000005htbOUAQ', 'Event_Date__c': '2015-08-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Summary__c': 'Accepted Subcommittee recommendation.', 'Formatted_Date__c': 'Aug 2015', 'Status_History__c': 'a132P000000AqxxQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 4 November 2015.', 'fs': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 4 November 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbPUAQ'}, 'Id': 'a0P2P000005htbPUAQ', 'Event_Date__c': '2015-11-04', 'Event_Description__c': 'Clinical advice received from Anti-Infective Subcommittee at meeting Wednesday 4 November 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-anti-infective-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Anti-Infective Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Nov 2015', 'Status_History__c': 'a132P000000Ar0uQAC'}, 'change': None}, {'Summary': {'s': 'Deferred making a recommendation and requested that the evidence in relation to the use of valganciclovir to prevent CMV reactivation during steroid pulse therapy and for the treatment or prophylaxis of Epstein - Barr virus be reviewed by the Transplant Immunosuppressant Subcommittee prior to PTAC making a recommendation.', 'fs': 'Deferred making a recommendation and requested that the evidence in relation to the use of valganciclovir to prevent CMV reactivation during steroid pulse therapy and for the treatment or prophylaxis of Epstein - Barr virus be reviewed by the Transplant Immunosuppressant Subcommittee prior to PTAC making a recommendation.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbQUAQ'}, 'Id': 'a0P2P000005htbQUAQ', 'Event_Date__c': '2016-02-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update-2.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'Deferred making a recommendation and requested that the evidence in relation to the use of valganciclovir to prevent CMV reactivation during steroid pulse therapy and for the treatment or prophylaxis of Epstein - Barr virus be reviewed by the Transplant Immunosuppressant Subcommittee prior to PTAC making a recommendation.', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar4hQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2016', 'fs': 'Jul 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbRUAQ'}, 'Id': 'a0P2P000005htbRUAQ', 'Event_Date__c': '2016-07-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2016', 'Status_History__c': 'a132P000000ArAAQA0'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that funding of oral valganciclovir be widened to include CMV prophylaxis for all transplant patients receiving pulse methylprednisolone for acute rejection after the initial course of CMV prophylaxis (variable depending on the organ) that requires a further 90 days of valganciclovir for CMV prophylaxis with a high priority.    The Subcommittee recommended that funding of oral valganciclovir be widened to include an additional 6 months of initial CMV prophylaxis for lung transplant patients (12 months total from time of transplant) if the quantiferon CMV-approach is used to determine prophylaxis requirement with high priority.', 'fs': 'The Subcommittee recommended that funding of oral valganciclovir be widened to include CMV prophylaxis for all transplant patients receiving pulse methylprednisolone for acute rejection after the initial course of CMV prophylaxis (variable depending on the organ) that requires a further 90 days of valganciclovir for CMV prophylaxis with a high priority.    The Subcommittee recommended that funding of oral valganciclovir be widened to include an additional 6 months of initial CMV prophylaxis for lung transplant patients (12 months total from time of transplant) if the quantiferon CMV-approach is used to determine prophylaxis requirement with high priority.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://https://www.pharmac.govt.nz/assets/ptac-transplant-immunosuppressant-subcommittee-minutes-2017-10.pdf"" target=""_blank"">Transplant Immunosuppressant Subcommittee minutes</a>', 'fs': '<a href=""https://https://www.pharmac.govt.nz/assets/ptac-transplant-immunosuppressant-subcommittee-minutes-2017-10.pdf"" target=""_blank"">Transplant Immunosuppressant Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2017', 'fs': 'Oct 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Transplant Immunosuppressant Subcommittee at meeting Tuesday 3 October 2017.', 'fs': 'Clinical advice received from Transplant Immunosuppressant Subcommittee at meeting Tuesday 3 October 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbSUAQ'}, 'Id': 'a0P2P000005htbSUAQ', 'Event_Date__c': '2017-10-03', 'Event_Description__c': 'Clinical advice received from Transplant Immunosuppressant Subcommittee at meeting Tuesday 3 October 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://https://www.pharmac.govt.nz/assets/ptac-transplant-immunosuppressant-subcommittee-minutes-2017-10.pdf"" target=""_blank"">Transplant Immunosuppressant Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee recommended that funding of oral valganciclovir be widened to include CMV prophylaxis for all transplant patients receiving pulse methylprednisolone for acute rejection after the initial course of CMV prophylaxis (variable depending on the organ) that requires a further 90 days of valganciclovir for CMV prophylaxis with a high priority.    The Subcommittee recommended that funding of oral valganciclovir be widened to include an additional 6 months of initial CMV prophylaxis for lung transplant patients (12 months total from time of transplant) if the quantiferon CMV-approach is used to determine prophylaxis requirement with high priority.', 'Formatted_Date__c': 'Oct 2017', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000ArLYQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbTUAQ'}, 'Id': 'a0P2P000005htbTUAQ', 'Event_Date__c': '2018-08-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArVMQA0'}, 'change': None}]",May 2015,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2015', 'fs': 'May 2015', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbNUAQ'}, 'Id': 'a0P2P000005htbNUAQ', 'Event_Date__c': '2015-05-11', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2015', 'Status_History__c': 'a132P000000AqvrQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbUUAQ'}, 'Id': 'a0P2P000005htbUUAQ', 'Event_Date__c': '2018-08-09', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArVQQA0'}, 'change': None}]",May 2015,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-11-12-valganciclovir/"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-11-12-valganciclovir/"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2020', 'fs': 'Nov 2020', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbVUAQ'}, 'Id': 'a0P2P000005htbVUAQ', 'Event_Date__c': '2020-11-12', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2020-11-12-valganciclovir/"" target=""_blank"">Consultation letter</a></p>', 'Formatted_Date__c': 'Nov 2020', 'Status_History__c': 'a132P000000CLKvQAO'}, 'change': None}]",Nov 2020,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-01-12-decision-to-widen-access-to-valganciclovir-for-transplant-patients/?type=Decision&amp;page=1"" target=""_blank"">Decision notification letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-01-12-decision-to-widen-access-to-valganciclovir-for-transplant-patients/?type=Decision&amp;page=1"" target=""_blank"">Decision notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jan 2021', 'fs': 'Jan 2021', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005htbWUAQ'}, 'Id': 'a0P2P000005htbWUAQ', 'Event_Date__c': '2021-01-18', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-01-12-decision-to-widen-access-to-valganciclovir-for-transplant-patients/?type=Decision&amp;page=1"" target=""_blank"">Decision notification letter</a></p>', 'Formatted_Date__c': 'Jan 2021', 'Status_History__c': 'a132P000000CWLfQAO'}, 'change': None}]",Jan 2021,False,True
